Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has received an average rating of “Buy” from the six analysts that are covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $6.25.
A number of equities research analysts have recently issued reports on the company. Oppenheimer Holdings, Inc. set a $11.00 target price on Catabasis Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, March 18th. Zacks Investment Research lowered Catabasis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, May 19th. Wedbush reiterated an “outperform” rating and issued a $4.00 target price on shares of Catabasis Pharmaceuticals in a research note on Wednesday, June 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 target price (down previously from $14.00) on shares of Catabasis Pharmaceuticals in a research note on Tuesday, March 21st.
Catabasis Pharmaceuticals (CATB) opened at 1.33 on Monday. The stock’s 50 day moving average price is $1.35 and its 200-day moving average price is $2.02. The firm’s market capitalization is $29.89 million. Catabasis Pharmaceuticals has a 12 month low of $1.08 and a 12 month high of $7.89.
Large investors have recently modified their holdings of the stock. Oppenheimer & Co. Inc. acquired a new stake in shares of Catabasis Pharmaceuticals during the first quarter worth $144,000. Renaissance Technologies LLC acquired a new stake in shares of Catabasis Pharmaceuticals during the first quarter worth $106,000. Finally, Federated Investors Inc. PA raised its stake in shares of Catabasis Pharmaceuticals by 45.1% in the fourth quarter. Federated Investors Inc. PA now owns 160,000 shares of the biotechnology company’s stock worth $578,000 after buying an additional 49,750 shares during the period. Hedge funds and other institutional investors own 32.82% of the company’s stock.
WARNING: This piece of content was reported by WKRB News and is the property of of WKRB News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.wkrb13.com/markets/2285091/catabasis-pharmaceuticals-inc-catb-given-consensus-rating-of-buy-by-analysts.html.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285091/catabasis-pharmaceuticals-inc-catb-given-consensus-rating-of-buy-by-analysts.html
Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.